Most syringes used for these medications are U-100 insulin syringes, where 100 units equal one milliliter (1 mL) of liquid
Local and regional compounding pharmacies also directly manufacture GLP-1s, with gray literature prices from $1800 to $3000 per year
Interestingly, the dual agonist tirzepatide has shown efficacy in neuroprotection, by counteracting hyperglycemia and insulin resistance-related effects at the neuronal level ( Also triple agonists have demonstrated to possess anti-neurodegenerative properties, indicating a potential for treating Alzheimers disease by reducing neuroinflammation and oxidative stress, enhancing neuronal health and viability, and minimizing glutamate excitotoxicity (Kopp et al., 2022)
The average timeline to significant results is 12 to 24 weeks, with maximum results around 48 weeks
One 10 mg vial provides roughly 1620 days of material at the 600 mcg/day target, and longer during the ramp weeks